PL3270923T3 - Środek terapeutyczny na zaburzenie czynności płata czołowego - Google Patents

Środek terapeutyczny na zaburzenie czynności płata czołowego

Info

Publication number
PL3270923T3
PL3270923T3 PL16765135T PL16765135T PL3270923T3 PL 3270923 T3 PL3270923 T3 PL 3270923T3 PL 16765135 T PL16765135 T PL 16765135T PL 16765135 T PL16765135 T PL 16765135T PL 3270923 T3 PL3270923 T3 PL 3270923T3
Authority
PL
Poland
Prior art keywords
disorder
therapeutic agent
frontal lobe
lobe
frontal
Prior art date
Application number
PL16765135T
Other languages
English (en)
Inventor
Takako Horita
Original Assignee
Kyowa Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co., Ltd. filed Critical Kyowa Kirin Co., Ltd.
Publication of PL3270923T3 publication Critical patent/PL3270923T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16765135T 2015-03-19 2016-03-18 Środek terapeutyczny na zaburzenie czynności płata czołowego PL3270923T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015055532 2015-03-19
EP16765135.5A EP3270923B1 (en) 2015-03-19 2016-03-18 Therapeutic agent for frontal lobe dysfunction
PCT/JP2016/059788 WO2016148308A1 (en) 2015-03-19 2016-03-18 Therapeutic agent for frontal lobe dysfunction

Publications (1)

Publication Number Publication Date
PL3270923T3 true PL3270923T3 (pl) 2021-12-20

Family

ID=56919157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16765135T PL3270923T3 (pl) 2015-03-19 2016-03-18 Środek terapeutyczny na zaburzenie czynności płata czołowego

Country Status (38)

Country Link
US (2) US20180042910A1 (pl)
EP (1) EP3270923B1 (pl)
JP (1) JP6869893B2 (pl)
KR (1) KR20170129764A (pl)
CN (1) CN107405341A (pl)
AR (1) AR103972A1 (pl)
AU (1) AU2016234211B2 (pl)
BR (1) BR112017018165A2 (pl)
CA (1) CA2978426A1 (pl)
CL (1) CL2017002351A1 (pl)
CO (1) CO2017008814A2 (pl)
CR (1) CR20170405A (pl)
CY (1) CY1124459T1 (pl)
DK (1) DK3270923T3 (pl)
DO (1) DOP2017000206A (pl)
EA (1) EA032511B1 (pl)
EC (1) ECSP17069712A (pl)
ES (1) ES2884846T3 (pl)
GE (2) GEAP201914604A (pl)
HR (1) HRP20211340T1 (pl)
HU (1) HUE055387T2 (pl)
IL (1) IL254196A0 (pl)
JO (1) JO3544B1 (pl)
LT (1) LT3270923T (pl)
MX (1) MX381277B (pl)
MY (1) MY196076A (pl)
PE (1) PE20171621A1 (pl)
PL (1) PL3270923T3 (pl)
PT (1) PT3270923T (pl)
RS (1) RS62311B1 (pl)
SG (1) SG11201707012YA (pl)
SI (1) SI3270923T1 (pl)
SV (1) SV2017005527A (pl)
TN (1) TN2017000369A1 (pl)
TW (1) TWI723012B (pl)
UA (1) UA123578C2 (pl)
WO (1) WO2016148308A1 (pl)
ZA (1) ZA201706136B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113016719B (zh) * 2019-12-24 2022-08-02 复旦大学附属华山医院 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers

Also Published As

Publication number Publication date
DK3270923T3 (da) 2021-08-23
SI3270923T1 (sl) 2021-10-29
MY196076A (en) 2023-03-13
CR20170405A (es) 2018-01-30
ECSP17069712A (es) 2018-02-28
LT3270923T (lt) 2021-09-10
CY1124459T1 (el) 2022-07-22
CA2978426A1 (en) 2016-09-22
WO2016148308A1 (en) 2016-09-22
ZA201706136B (en) 2019-01-30
JP2018508540A (ja) 2018-03-29
TWI723012B (zh) 2021-04-01
ES2884846T3 (es) 2021-12-13
CO2017008814A2 (es) 2018-01-16
GEP20197007B (en) 2019-07-25
KR20170129764A (ko) 2017-11-27
TN2017000369A1 (en) 2019-01-16
GEAP201914604A (en) 2019-02-25
BR112017018165A2 (pt) 2018-04-10
EA032511B1 (ru) 2019-06-28
IL254196A0 (en) 2017-10-31
EP3270923A1 (en) 2018-01-24
DOP2017000206A (es) 2017-12-31
RS62311B1 (sr) 2021-09-30
MX381277B (es) 2025-03-12
AU2016234211A1 (en) 2017-10-12
US20180042910A1 (en) 2018-02-15
US20210393606A1 (en) 2021-12-23
HRP20211340T1 (hr) 2021-11-26
HUE055387T2 (hu) 2021-11-29
SG11201707012YA (en) 2017-09-28
EA201792070A1 (ru) 2018-01-31
EP3270923B1 (en) 2021-05-26
HK1249059A1 (zh) 2018-10-26
EP3270923A4 (en) 2018-11-07
PE20171621A1 (es) 2017-11-02
MX2017012020A (es) 2018-01-30
CL2017002351A1 (es) 2018-03-16
JP6869893B2 (ja) 2021-05-12
CN107405341A (zh) 2017-11-28
AR103972A1 (es) 2017-06-14
TW201705957A (zh) 2017-02-16
UA123578C2 (uk) 2021-04-28
PT3270923T (pt) 2021-08-26
JO3544B1 (ar) 2020-07-05
SV2017005527A (es) 2017-10-23
AU2016234211B2 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
DK3328880T3 (da) Terapeutiske midler
EP3463464A4 (en) ASSOCIATION TREATMENT
PT3283527T (pt) Terapêutica de combinação para o cancro
EP3291824A4 (en) ANTIMICROBIAL THERAPY
LT3423103T (lt) Pth provaistai
GB201509893D0 (en) Therapeutic agents
HUE050705T2 (hu) A rákos megbetegedések kezelésére szolgáló uridin diolaxán analógjai
MA39483A (fr) Agents thérapeutiques cibles
EP3311841A4 (en) ANTI CANCER AGENTS
GB201517263D0 (en) Therapeutic agents
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
EP3307268A4 (en) SUBSTITUTED PHENYLOXAZOLIDINONE FOR ANTIMICROBIAL THERAPY
PL3259232T3 (pl) Sposób na aerożele
HUE060732T2 (hu) Terápiás szer fibrózisra
GB201509885D0 (en) Therapeutic agents
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
EP3308781A4 (en) BLOOD PRESSURE CENTER
GB201509888D0 (en) Therapeutic agents
EP3334447A4 (en) CCK2R-drug conjugates
EP3305294A4 (en) AQUEOUS MEDICINE
LT3324951T (lt) Peritoninis terapinis skystis
GB201513299D0 (en) Therapeutic agents
EP3349853A4 (en) PRODRUGS OF FENCAMFAMINE